Point72 Hong Kong LTD Clovis Oncology, Inc. Transaction History

Point72 Hong Kong LTD

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $8,779 - $41,250	-13,936 Reduced 91.67%	1,267 $2,000
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $12,040 - $26,438	-8,420 Reduced 35.64%	15,203 $31,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $63,782 - $112,445	23,623 New	23,623 $64,000
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $61,565 - $95,553	-14,907 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.82 - $7.72 $70,015 - $112,140	14,526 Added 3812.6%	14,907 $87,000
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $5,109 - $8,701	-898 Reduced 70.21%	381 $3,000
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $4,821 - $14,069	1,279 New	1,279 $8,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $36,087 - $197,636	-12,029 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $47,273 - $184,645	12,029 New	12,029 $47,000
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $18,664 - $37,401	-1,457 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $25,236 - $43,270	1,429 Added 5103.57%	1,457 $36,000
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $29,865 - $83,896	-2,568 Reduced 98.92%	28 $1,000
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $76,244 - $128,450	2,596 New	2,596 $76,000
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $4,921 - $7,300	-117 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $12,129 - $16,388	-242 Reduced 67.41%	117 $6,000
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $20,710 - $30,364	359	359 $24,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.